Corindus Vascular Robotics Priced, NYSE: CVRS

Sells robotic systems that aid stent placement during coronary angioplasties.

Industry: Health Care

Latest Trade: $1.18 0.00 (0.0%)

First Day Return: +5.3%

Return from IPO: -68.9%

Industry: Health Care

We design, manufacture and sell precision vascular robotic-assisted systems for use in interventional vascular procedures,the CorPath System. Our first and current product, the CorPath 200 System, is the only vascular robotic system cleared by the FDA to bring precision and accuracy to stent placement in percutaneous coronary intervention procedures. While we are initially cleared for and are targeting PCI procedures, we believe our technology platform has the capability to be developed in the future for other segments of the vascular market, including peripheral vascular, neurointerventional and other more complex cardiac interventions such as structural heart. As of March 31, 2015, we have installed 26 CorPath Systems in hospitals in the U.S. and two CorPath Systems in hospitals outside of the U.S.
more less
IPO News for Corindus Vascular Robotics
more
IPO Data
IPO File Date 05/11/2015
Offer Price $3.80
Price Range $3.80 - $3.80
Offer Shares (mm) 11.0
Deal Size ($mm) $42
IPO Data
IPO Date 05/28/2015
Offer Price $3.80
Price Range $3.80 - $3.80
Offer Shares (mm) 11.0
Deal Size ($mm) $42
Underwriters
more
Company Data
Headquarters Waltham, MA
Founded 2011
Employees 68
Website www.corindus.com